Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
Lantern Pharma Inc. (LTRN), a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on March 18, 2024. The filing announces the release of financial results for the fiscal year and fourth quarter ended December 31, 2023.
Key Financial Metrics
The provided text serves as a notification of the results release and does not contain specific financial data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this filing text.
Material Changes
No material changes or comparative financial data are detailed in this document. The filing references a press release (Exhibit 99.1) and a presentation (Exhibit 99.2) for the actual financial figures and operational updates.
Guidance, Outlook, and Risks
The Company scheduled a conference call and live webinar on March 18, 2024, to discuss the financial and operating results. The filing includes standard disclaimers stating that the information in Items 2.02 and 7.01, including the exhibits, is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section unless expressly incorporated by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the year ended December 31, 2023.
- Examine Exhibit 99.2 (Presentation) for management's outlook, pipeline updates, and guidance for the upcoming fiscal year.
- Verify the details of the conference call and webinar to understand the context of the reported results.
- Confirm the company's status as an emerging growth company and any associated accounting election impacts.